Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Serum baseline tryptase (sBT) is a minor diagnostic criterion for systemic mastocytosis (SM) of undetermined prognostic impact. We monitored sBT levels in indolent SM (ISM) patients and investigated its utility for predicting disease behaviour and outcome. METHODS: In total 74 adult ISM patients who were followed for ≥48 months and received no cytoreductive therapy were retrospectively studied. Patients were classified according to the pattern of evolution of sBT observed. RESULTS: Overall 16/74 (22%) cases had decreasing sBT levels, 48 (65%) patients showed increasing sBT levels and 10 (13%) patients showed a fluctuating pattern. Patients with significantly increasing sBT (sBT slope ≥0.15) after 48 months of follow-up showed a slightly greater rate of development of diffuse bone sclerosis (13% vs. 2%) and hepatomegaly plus splenomegaly (16% vs. 5%), as well as a significantly greater frequency of multilineage vs. mast cells (MC)-restricted KIT mutation (p = 0.01) together with a greater frequency of cases with progression of ISM to smouldering and aggressive SM (p = 0.03), and a shorter progression-free survival (p = 0.03). CONCLUSIONS: Monitoring of sBT in ISM patients is closely associated with poor prognosis disease features as well as with disease progression, pointing out the need for a closer follow-up in ISM patients with progressively increasing sBT values.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784 · cited 1×
“Increased total serum baseline tryptase (sBT) -recorded in the absence of acute MC mediator release episodes- has long been described in ISM [16,17], and sBT levels .”
BackgroundSchwartz, L. B., Sakai, K., Bradford, T. R., Ren, S., Zweiman, B., Worobec, A. S., & Metcalfe, D. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118337 · Cited by 371 · cited 3×
“associated with the formation of enzymatically inactive tetramers [14,15], and it is constitutively released from MC into the plasma [16].”
BackgroundEvaluation of human peripheral blood leukocytes for mast cell tryptase
Castells, M. C., Irani, A. M., & Schwartz, L. B. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.7.2184 · Cited by 278
Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis
Schwartz, L. B., Bradford, T. R., Rouse, C., Irani, A.-M., Rasp, G., Van Der Zwan, J. K., & Van Der Linden, P.-W. G. (1994) · Journal of Clinical Immunology · doi:10.1007/bf01533368 · Cited by 263
Sperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000059404 · Cited by 207
Self-citationvan der Linden, P.-W. G., Hack, C. E., Poortman, J., Vivié-Kipp, Y. C., Struyvenberg, A., & van der Zwan, J. K. (1992) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(06)80017-5 · Cited by 164 · cited 1×
“However, markedly increased sBT have also been found in disease conditions other than mastocytosis such as anaphylactic episodes [16,23] associated or not with hymenoptera venom sting [24], clonal myeloid malignancies [22], a subset of hypereosinophilic syndromes [25], chronic urticaria [26] and advanced kidney diseas…”
BackgroundCharacterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3
Pallaoro, M., Fejzo, M. S., Shayesteh, L., Blount, J. L., & Caughey, G. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3355 · Cited by 146 · cited 1×
“Although all four forms of tryptase are coded by genes localized in chromosome 16 [11,12]; they show a different pattern of expression in serum.”
BackgroundClinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders
Schwartz, L. B. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00020-0 · Cited by 110
Sperr, W. R., El‐Samahi, A., Kundi, M., Girschikofsky, M., Winkler, S., Lutz, D., Endler, G., Rumpold, H., Agis, H., Sillaber, C., et al. (2009) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02184.x · Cited by 98 · cited 1×
“However, markedly increased sBT have also been found in disease conditions other than mastocytosis such as anaphylactic episodes [16,23] associated or not with hymenoptera venom sting [24], clonal myeloid malignancies [22], a subset of hypereosinophilic syndromes [25], chronic urticaria [26] and advanced kidney diseas…”
BackgroundSerum total tryptase levels are increased in patients with active chronic urticaria
Ferrer, M., Nuñez‐Córdoba, J. M., Luquin, E., Grattan, C. E., De la Borbolla, J. M., Sanz, M. L., & Schwartz, L. B. (2010) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2010.03582.x · Cited by 72 · cited 1×
“However, markedly increased sBT have also been found in disease conditions other than mastocytosis such as anaphylactic episodes [16,23] associated or not with hymenoptera venom sting [24], clonal myeloid malignancies [22], a subset of hypereosinophilic syndromes [25], chronic urticaria [26] and advanced kidney diseas…”
Background
Cited by
Valent, P., Escribano, L., Broesby‐Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., et al. (2014) · Allergy · doi:10.1111/all.12436 · Cited by 174
Self-citationHuman mast cell tryptase in biology and medicine
Vitte, J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.04.001 · Cited by 152
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Jara-Acevedo, M., Teodosio, C., Sanchez-Muñoz, L., Álvarez-Twose, I., Mayado, A., Caldas, C., Matito, A., Morgado, J. M., Muñoz-González, J. I., Escribano, L., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.72 · Cited by 114
Self-citationSystemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0088 · Cited by 106
Metadata
- Authors
- Matito, A., Morgado, J. M., Álvarez-Twose, I., Sánchez-Muñoz, L., Pedreira, C. E., Jara-Acevedo, M., Teodosio, C., Sánchez-López, P., Fernández-Núñez, E., Moreno-Borque, R., García-Montero, A., Orfao, A., & Escribano, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-14
- Volume
- 8
- Issue
- 10
- Pages
- e76116
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1983104005
- Cited by
- 37
- References
- 12
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.